ImmuCell Corp
ICCC5.970USD
-0.170-2.77%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
54.00MMarket Cap
21.77P/E TTM
More Details of ImmuCell Corp Company
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
ImmuCell Corp Info
Ticker SymbolICCC
Company nameImmuCell Corp
IPO dateMay 01, 1987
CEOte Boekhorst (Olivier)
Number of employees69
Security typeOrdinary Share
Fiscal year-endMay 01
Address56 Evergreen Drive
CityPORTLAND
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code04103
Phone12078782770
Websitehttps://immucell.com/
Ticker SymbolICCC
IPO dateMay 01, 1987
CEOte Boekhorst (Olivier)
Company Executives of ImmuCell Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
215.75K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
133.43K
+1.24%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
215.75K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
133.43K
+1.24%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
First Defense® product line
6.40M
99.28%
Other animal health
46.36K
0.72%
By RegionUSD
Name
Revenue
Proportion
United States
4.87M
75.63%
Other
1.57M
24.37%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
First Defense® product line
6.40M
99.28%
Other animal health
46.36K
0.72%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knudsen (Ejnar A III)
9.21%
Pessin (Norman H)
7.12%
Rothschild (Jonathan E)
5.68%
SRK Capital, LLC
5.55%
Pessin (Sandra F)
4.44%
Other
68.00%
Shareholders
Shareholders
Proportion
Knudsen (Ejnar A III)
9.21%
Pessin (Norman H)
7.12%
Rothschild (Jonathan E)
5.68%
SRK Capital, LLC
5.55%
Pessin (Sandra F)
4.44%
Other
68.00%
Shareholder Types
Shareholders
Proportion
Individual Investor
32.25%
Investment Advisor
14.31%
Investment Advisor/Hedge Fund
3.60%
Hedge Fund
1.98%
Research Firm
0.02%
Other
47.84%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
46
1.81M
20.03%
-84.61K
2025Q2
56
4.25M
46.97%
-88.13K
2025Q1
59
4.81M
59.23%
+487.91K
2024Q4
58
4.30M
48.30%
+425.64K
2024Q3
56
4.25M
49.53%
+427.28K
2024Q2
57
3.67M
43.77%
+363.56K
2024Q1
55
3.19M
41.22%
-172.12K
2023Q4
55
3.22M
41.55%
-93.50K
2023Q3
57
3.23M
41.67%
-83.77K
2023Q2
56
3.25M
41.94%
-58.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knudsen (Ejnar A III)
463.62K
5.13%
--
--
Apr 14, 2025
Pessin (Norman H)
644.02K
7.12%
--
--
Apr 14, 2025
Rothschild (Jonathan E)
514.00K
5.68%
--
--
Apr 14, 2025
SRK Capital, LLC
502.26K
5.55%
--
--
Apr 14, 2025
Pessin (Sandra F)
401.82K
4.44%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
308.70K
3.41%
+83.11K
+36.84%
Jun 30, 2025
Brigham (Michael F)
215.75K
2.39%
--
--
Apr 14, 2025
Renaissance Technologies LLC
159.99K
1.77%
+26.00K
+19.40%
Jun 30, 2025
Pessin (Brian L)
136.88K
1.51%
--
--
Apr 14, 2025
Tomsche (David Scott)
131.80K
1.46%
+24.37K
+22.69%
Apr 14, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ImmuCell Corp?
The top five shareholders of ImmuCell Corp are:
Knudsen (Ejnar A III) holds 463.62K shares, accounting for 5.13% of the total shares.
Pessin (Norman H) holds 644.02K shares, accounting for 7.12% of the total shares.
Rothschild (Jonathan E) holds 514.00K shares, accounting for 5.68% of the total shares.
SRK Capital, LLC holds 502.26K shares, accounting for 5.55% of the total shares.
Pessin (Sandra F) holds 401.82K shares, accounting for 4.44% of the total shares.
Knudsen (Ejnar A III) holds 463.62K shares, accounting for 5.13% of the total shares.
Pessin (Norman H) holds 644.02K shares, accounting for 7.12% of the total shares.
Rothschild (Jonathan E) holds 514.00K shares, accounting for 5.68% of the total shares.
SRK Capital, LLC holds 502.26K shares, accounting for 5.55% of the total shares.
Pessin (Sandra F) holds 401.82K shares, accounting for 4.44% of the total shares.
What are the top three shareholder types of ImmuCell Corp?
The top three shareholder types of ImmuCell Corp are:
Knudsen (Ejnar A III)
Pessin (Norman H)
Rothschild (Jonathan E)
Knudsen (Ejnar A III)
Pessin (Norman H)
Rothschild (Jonathan E)
How many institutions hold shares of ImmuCell Corp (ICCC)?
As of 2025Q3, 46 institutions hold shares of ImmuCell Corp, with a combined market value of approximately 1.81M, accounting for 20.03% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -26.94%.
What is the biggest source of revenue for ImmuCell Corp?
In FY2025Q2, the First Defense® product line business generated the highest revenue for ImmuCell Corp, amounting to 6.40M and accounting for 99.28% of total revenue.
